Business Context and Reporting Period
Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Relmada is a clinical-stage biotechnology company focused on developing esmethadone (REL-1017), an NMDA receptor antagonist for depression, and a modified-release psilocybin formulation (REL-P11) for metabolic indications. The company has no commercial products and has not generated revenue.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(21,725,970) | $(61,322,218) | $(73,626,588) |
| Loss Per Share (Basic/Diluted) | $(0.72) | $(2.03) | $(2.45) |
| Operating Expenses | $23,008,838 | $64,815,482 | $76,872,973 |
| Cash & Cash Equivalents (Sep 30, 2024) | $1,483,789 | ||
| Short-Term Investments (Sep 30, 2024) | $52,633,938 | ||
| Total Current Assets | $55,702,530 | ||
| Total Current Liabilities | $8,086,761 | ||
| Accumulated Deficit | $(622,224,899) | ||
| Operating Cash Flow (YTD) | $(42,956,164) |
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss for the nine months ended September 30, 2024, decreased by approximately $12.3 million compared to the same period in 2023, primarily driven by reduced operating expenses.
- Operating Expenses: Total operating expenses decreased by $12.1 million year-over-year.
- Research & Development (R&D): Decreased by $4.9 million due to the completion of the long-term open-label study (Study 310) and prior Phase 3 trials (RELIANCE I and III), partially offset by the ramp-up of new studies (302 and 304).
- General & Administrative (G&A): Decreased by $7.2 million, largely attributed to a $10 million reduction in stock-based compensation as older equity grants vested and fewer new options were granted due to shareholder plan limitations.
- Liquidity Position: Cash and cash equivalents decreased from $4.1 million at year-end 2023 to $1.5 million at September 30, 2024. Short-term investments decreased from $92.2 million to $52.6 million as the company utilized funds for operations.
- Investment Income: Interest and investment income decreased due to lower interest rates and yields, though the company recorded net realized and unrealized gains on short-term investments in 2024 compared to losses in 2023.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. The company projects insufficient liquidity to sustain operations for one year following the issuance of these financial statements. No adjustments have been made to the financial statements to reflect potential asset recoverability or liability classification changes.
- Financing Needs: The company is evaluating financing strategies, including public or private equity/debt sales, loans, or strategic collaborations. There is no assurance that funding will be secured on favorable terms or at all.
- Clinical Pipeline Updates:
- Esmethadone (REL-1017): Two Phase 3 trials (RELIANCE I and III) failed to meet primary endpoints in late 2022. The company is conducting an interim analysis of the RELIANCE II trial (expected by year-end 2024) and the RELIGHT trial.
- Psilocybin (REL-P11): The company plans to initiate a Phase 1 trial in obese subjects in 2024 to evaluate a modified-release formulation for metabolic indications.
- Stock-Based Compensation: Significant reductions in stock-based compensation expenses were noted due to the expiration of vesting periods for prior grants and a lack of shareholder approval to increase the 2021 Equity Incentive Plan, limiting new option grants.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for cash depletion and the status of any ongoing financing discussions or agreements.
- RELIANCE II Interim Analysis: Monitor the upcoming year-end 2024 interim analysis results for the RELIANCE II Phase 3 trial, which is critical for the future of the lead asset.
- Equity Plan Constraints: Review the status of the 2021 Equity Incentive Plan and potential shareholder votes required to authorize new equity grants, which impacts future compensation costs and employee retention.
- Going Concern Mitigation: Assess the probability and terms of potential capital raises given the current market environment and the company's accumulated deficit of over $622 million.
- Psilocybin Program Progress: Confirm the initiation date and design of the Phase 1 trial for REL-P11 in 2024.